Source - SMW
Verseon has presented a second development candidate for clinical trials from its anticoagulation program at the American Heart Association's Scientific Sessions 2017. 

VE-2851 shows excellent efficacy paired with low bleeding risk in pre-clinical testing and is expected to enter clinical trials in 2018, the company said.


At 9:42am: (LON:VSN) Verseon Corporation Plc share price was 0p at 125p